Zoetis Beats Estimates but Shares Fall

The animal health company reported higher third-quarter earnings while U.S. companion animal revenue declined amid cost pressures on pet owners.

Updated on Nov. 5, 2026 in Pet Health

Live Poll

Do you expect your pet care costs to rise over the next year?

Zoetis reported third-quarter adjusted earnings of $1.75 per share, above analysts' consensus of $1.51, on sales of $2.391 billion. Its shares fell 6.10% to $83.76 on the report day as revenue declined 1% on a reported and organic operational basis.

Why it matters

U.S. companion animal revenue fell 8% as pet owners face cost pressures and clinic visits decline, signaling reduced spending on pet care. The results reflect competition from generic products and softer demand in the U.S. market.

Zoetis reported third-quarter sales of $2.391 billion and U.S. segment revenue of $1.2 billion, down 6%. U.S. companion animal revenue fell 8% while livestock revenue rose 5%, and the filing does not break out how much of the decline is tied to generic competition versus price sensitivity.

The players

Zoetis

Zoetis is a global animal health company that develops medicines, vaccines and diagnostics for companion animals and livestock.

The details

Companion animal revenue declined due to macro-driven price sensitivity, competitive pressure in dermatology, and generic competition from products such as Convenia and Cerenia. The company raised its fiscal 2026 adjusted EPS guidance to $6.25-$6.35 from $6.15-$6.25.

Year-to-date 2026: U.S. clinic visits were down 3% across categories.
Third quarter 2026: Canine vet visits fell around 5%.
Thursday, November 5, 2026: Shares fell 6.10% to $83.76 following the earnings report.
2027: Limited contribution from new commercial launches is expected.
2028: Impact of new commercial strategies is expected to build.

Market Landscape

Generic competition from products such as Convenia and Cerenia is eroding volumes for companion animal drugs, and the decline is compounded by weaker U.S. clinic traffic. Zoetis is betting that new launches will offset these pressures starting in 2027 and building into 2028.

Pet owners facing cost pressures may delay or reduce routine veterinary care, and clinic visits are already down 3% year-to-date across categories. Canine vet visits fell around 5% in the third quarter, showing how household budgets are shaping care decisions.

The takeaway

Rising pet care costs are pushing owners to make tradeoffs, so tracking veterinary visit trends can help households plan preventive care within their budgets. Watching how clinics adjust pricing and services can also inform decisions about routine treatments.